购物车
- 全部删除
- 您的购物车当前为空
12(S)-HETrE是一种内源性代谢物,由血小板中的12-脂氧合酶(12-LOX)氧化ω-6 PUFA dihomo-γ-linolenic acid(DGLA)产生,作用于Gαs偶联的G蛋白偶联受体,具有抗血栓形成的作用,在心血管疾病具有潜在的治疗作用。12(S)-HETrE 在体外可抑制激动剂介导的血小板活化(IC50 = 40 μM)、α 颗粒分泌、整合素 αⅡbβ3 活化、Rap1 活化和凝血酶诱导的血块回缩。
12(S)-HETrE是一种内源性代谢物,由血小板中的12-脂氧合酶(12-LOX)氧化ω-6 PUFA dihomo-γ-linolenic acid(DGLA)产生,作用于Gαs偶联的G蛋白偶联受体,具有抗血栓形成的作用,在心血管疾病具有潜在的治疗作用。12(S)-HETrE 在体外可抑制激动剂介导的血小板活化(IC50 = 40 μM)、α 颗粒分泌、整合素 αⅡbβ3 活化、Rap1 活化和凝血酶诱导的血块回缩。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 μg | ¥ 1,610 | 35日内发货 | |
50 μg | ¥ 2,970 | 35日内发货 | |
100 μg | ¥ 5,790 | 35日内发货 |
产品描述 | 12(S)-HETrE is an endogenous metabolite produced by oxidation of ω-6 PUFA dihomo-γ-linolenic acid (DGLA) by 12-lipoxygenase (12-LOX) in platelets, which acts on Gαs-coupled G-protein-coupled receptors, has antithrombotic properties, and has potential therapeutic use in cardiovascular disease. 12(S)-HETrE is reported to inhibit agonist-mediated platelet activation (IC50 = 40 μM), α granule secretion, integrin αIIbβ3 activation, Rap1 activation, and thrombin-induced clot retraction in vitro. |
体外活性 | 12(S)-HETrE (20,40 μM )处理血小板,在40μM的浓度下,血小板对其敏感,其对血小板可以产生抑制作用。[1] |
分子量 | 322.48 |
分子式 | C20H34O3 |
CAS No. | 72710-10-2 |
Smiles | C(\[C@H](C/C=C\CCCCC)O)=C/C=C\CCCCCCC(O)=O |
存储 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
溶解度信息 | 0.1 M Na2CO3: 4.00 mg/mL (12.40 mM), Sonication is recommended. PBS (pH 7.2): < 1 mg/ml (slightly soluble or insoluble), Sonication is recommended. | ||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||
0.1 M Na2CO3
|
评论内容